Browsing by Author "Vidal, M."

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Analysis of apheresis outcomes in a cohort of Chilean patients treated with autologous stem cell transplantation: A single center real-world experience
    (2024) Sarmiento, M.; Salinas, J.; Rojas, P.; Gutierrez, C.; Vidal, M.; Jara, V; Garcia, M. J.; Campbell, M. J.; Flores, Y.; Sandoval, V; Vergara, M.; Palacios, F.; Ocqueteau, M.
    Adequate stem cell harvesting is required for autologous hematopoietic transplantation. In deficient mobilizer patients, the collection of stem cells can be challenging because of the impossibility of achieving satisfactory CD34 cell counts with GCSF + - chemotherapy. Plerixafor is a potent and expensive drug that promotes the release of stem cells from the medullary niche to the peripheral blood and allows satisfactory harvests. We performed a retrospective analysis of 370 patients with myeloma and lymphoma harvested at our institution. 99 % of patients achieved satisfactory apheresis using Plerixafor in 45 %. Satisfactory harvests were obtained in patients mobilized with GCSF or plerixafor. In patients who used plerixafor, it was necessary to perform fewer apheresis procedures (P = 0.05). In multivariate analysis, the only factor that predicted the need for plerixafor was the presence of less than 30,000 CD34 / ul on the day of apheresis (OR 0.3. p < 0.001). Since we adopted the plerixafor protocol guided by CD34 counts, the number of patients with harvest failure has decreased. In conclusion, the rational and standardized use of plerixafor favors satisfactory harvest in patients who require autologous transplantation in South-American patients.
  • Thumbnail Image
    Item
    Galaxy Clusters in the Line of Sight to Background Quasars. I. Survey Design and Incidence of Mg II Absorbers at Cluster Redshifts
    (2008) Lopez, S.; Barrientos, L. F.; Lira, P.; Padilla, N.; Gilbank, D. G.; Gladders, M. D.; Maza, J.; Tejos, N.; Vidal, M.; Yee, H. K. C.
  • Thumbnail Image
    Item
    Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/ HER2-negative breast cancer patients undergoing preoperative endocrine therapy
    (2025) Gómez-Bravo, R.; Walbaum, B.; Bergamino, M.; Martínez-Sáez, O.; Schettini, F.; Seguí, E.; García-Fructuoso, I.; Pascual, T.; Chic, N.; González, M.; Rodríguez, A.; Rey, M.; Giménez-Xavier, P.; Blasco, P.; Castillo, O.; Galván, P.; Sanfeliu, E.; González-Farré, B.; Vidal, M.; Adamo, B.; Brasó-Maristany, F.; Prat, A.; Muñoz, M.
    Background: Early decrease in Ki67 after a short preoperative course of endocrine therapy (ET) has shown prognostic and predictive value in clinical research, but its applicability and reproducibility in routine clinical practice remain largely unknown. We therefore assessed on-treatment Ki67 changes following a short preoperative ET and its association with biological variables, such as intrinsic subtype and risk of recurrence (ROR), plus long-term outcomes, in a real-world cohort of patients with early estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-negative) breast cancer. Methods: We conducted a retrospective, registry-based analysis of 230 consecutive patients with early ER+/HER2− breast cancer treated as per standard clinical care at the Breast Unit of the Clinic Barcelona Comprehensive Cancer Center between 2014 and 2023. All patients received preoperative ET, tamoxifen, or an aromatase inhibitor (AI), for 2-12 weeks before surgery. Clinical and pathological variables were collected and stratified by Ki67 response: “responders” (post-treatment Ki67 0% to 10%) and “complete cell cycle arrest (CCCA) responders” (Ki67 ≤2.7%). PAM50/Prosigna was used to determine intrinsic subtypes and ROR-score. Event-free survival was estimated using Kaplan—Meier curves, and associations were tested using Cox proportional hazards regression. Results: The median duration of preoperative ET was 5 weeks (min-max range, 2-12 weeks). Overall, 196 patients (85.2%) met the Ki67 response criterion and 111 (48.3%) achieved CCCA. Response rates were significantly higher in postmenopausal compared with premenopausal women (P = 0.004). Notably, 95.6% of postmenopausal patients received an AI, whereas all premenopausal women were treated with tamoxifen. Additionally, response varied by intrinsic subtype, favoring Luminal A tumors (P = 0.047). In multivariable models, postmenopausal status and higher baseline ER expression were independently associated with both Ki67 response and CCCA, whereas a lower baseline ROR-score predicted CCCA. After a median follow-up of 47 months, CCCA was associated with significantly improved event-free survival [hazard ratio (HR) = 0.19; 95% CI (confidence interval) 0.05-0.72; P value = 0.012]. Conclusion: In routine practice, a short course of preoperative ET yields substantial reductions in tumor proliferation. Early assessment of Ki67 suppression offers a readily accessible indicator of endocrine sensitivity, and achieving CCCA identifies patients who have a more favorable prognosis and thus are potentially eligible to de-escalate in treatment strategies.
  • Thumbnail Image
    Item
    Lymphoma-like lesion of the cervix with monoclonal immunoglobulin heavy chain gene rearrangement in PCR analysis. A case report
    (2012) Zoroquiain Vélez, José Pablo; Vidal, M.; Valbuena Mora, José Rafael
    Resumen La lesión del cérvix es una proliferación linfoide benigna que simula un linfoma B difuso de células grandes, por ello es causa de potencial error diagnóstico. Presentamos el caso de una mujer de 24 años con PAP atípico y conización subsecuente, identificándose una proliferación linfoide atípica. El infiltrado linfoide era polimórfico, con numerosas células grandes entremezcladas, sin necrosis ni esclerosis. El epitelio presentó displasia epitelial moderada. Las células grandes fueron inmunorreactivas para CD20, sin expresión de cadenas ligeras de inmunoglobulinas. La hibridación in situ para el virus de Epstein-Barr resultó positiva en escasas células grandes aisladas. Mediante técnica de PCR, para amplificación de la región FR3 de la cadena pesada de la IgH, se observaron 2 bandas monoclonales. Hasta el último seguimiento (24 meses), no se encontró evidencia de enfermedad sistémica/progresión.
  • Thumbnail Image
    Item
    Place-of-death preferences among patients with cancer and family caregivers in inpatient and outpatient palliative care
    (2020) Vidal, M.; Rodríguez Núñez, Alfredo; Hui, D.; Allo, J.; Williams, J. L.; Park, M.; Liu, D.; Bruera, E.